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ABSTRACT: 
Purpose: Radial artery occlusion flowing cardiac catheterisation has been linked to flow 
reduction and prolonged compression. We investigate whether these factors can be 
optimised following transradial cardiac catheterisation by using an accelerated band 
removal protocol facilitated by a haemostasis promoting pad, in combination with a patent 
haemostasis technique. 
Methods: In this single centre prospective study, 389 consecutive patients undergoing TRA 
for coronary angiography or angioplasty were randomised to two haemostasis protocols: 
use of a Helix™ compression device alone (HC) or in combination with a haemostatic pad 
(StatSeal® disc) and an accelerated haemostasis protocol (AC). A patent haemostasis 
technique was employed in both study arms. The primary efficacy endpoint was the time to 
haemostasis and the secondary safety outcome was access site related complications: re-
bleeding, haematoma and radial artery patency assessed within 24 hours using reverse 
Barbeau’s Test (BT). 
Results: Between May and Nov 2017, 191 patients were randomised to receive HC and 198 
patients to AC. Compression time was significantly higher with HC as compared to AC (165.8 
± 63.1 versus 79.7 ± 41.2 minutes, p<0.001). There were no significant differences in re-
bleeding and RAO between groups (3.7% versus 5.6%, p=0.37 and 6.3% versus 4.1%, p=0.33) 
respectively. Incidence of haematoma was higher in AC group (4.7% versus 12.1%, p=0.009).  
Conclusion: A reduction in radial artery compression time can be achieved by using Statseal 
in association with an accelerated haemostasis protocol without increasing the risk of access 
site bleeding and RAO. The combination of reduced compression time combined with 
maintained radial flow via patent haemostasis has the potential to reduce the risk of radial 
occlusion after transradial catheterisation. 
 
Key words: StatSeal, Helix compression device, Rapid deflation technique 
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INTRODUCTION 
Use of transradial access (TRA) for cardiac catheterization procedures is increasing 
worldwide.1, 2 TRA offers significant patient benefits over transfemoral access (TFA) with 
fewer access site complications, improved patient comfort, reduced costs and a reduction in 
MACE in high risk groups.3-8 In view of this, the most recent European Society of Cardiology 
guidelines for management of non-ST elevation myocardial infarction (NSTEMI), recommend 
TRA with a class 1A indication, for invasive management of NSTEMI with PCI.9  However, the 
transradial approach is still not free from access site complications although they are low in 
comparison to TFA.6, 7, 10-12 In comparison to the femoral artery, the radial artery is small, 
superficial and easily compressible. This facilitates haemostasis following procedures and 
the use of dedicated haemostasis devices allows for almost immediate ambulation of 
patients, reducing post procedure nursing input.13-15 
Since the introduction of TRA, there have been many advances to achieve optimal 
haemostasis, predominantly in an effort to minimise complications, improve patient 
comfort and reduce radial artery occlusion (RAO).16, 17 Optimising haemostasis with gentler, 
less prolonged and patent haemostasis has been shown to be associated with lower rates of 
RAO.10, 18 
A reduction in haemostasis time following TRA procedures potentially lessens  amount of 
nursing input required, facilitates early discharge, reduces overall costs and has the 
potential to reduce radial artery occlusion rate.14 Materials to promote haemostasis have 
previously been used to facilitate removal of venous and dialysis lines.13 At our high volume 
radial centre we sought to evaluate a new accelerated haemostasis protocol (AHP) using our 
standard haemostasis compression device, the Helix TM (Figure 1A) with the addition of a 
haemostasis promoting disc (Figure 1B) in combination with a standard patent haemostasis 
technique. 
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METHODS 
STUDY POPULATION AND RECRUITMENT  
This study was a prospective, single-centre, open-label, randomized controlled trial to 
evaluate two haemostasis protocols following TRA coronary procedures. All patients 
presenting to our institution between May and November 2017 for coronary procedures 
irrespective of the indication were enrolled. Patients were excluded if radial access was not 
used, or if they were planned to be transferred to other hospitals after completion of 
procedure before the compression device had been removed. Patients were randomised to 
either an accelerated haemostasis protocol with a haemostasis promoting disc (AC group), 
or standard compression with Helix alone (HC group). The haemostasis promoting material 
is a 14mm diameter disc (StatSeal® Advanced), comprised of a hydrophilic polymer that 
dehydrates blood and potassium ferrate, a compound that agglomerates blood solids to 
create a seal without interfering with the normal haematological clotting process.  
PROCEDURAL DETAILS 
All procedures were carried out as standard using 5F or 6F radial sheaths (Terumo, 
Glidesheath Slender).  All patients received heparin (at least 5000 iu for diagnostic 
procedures and 70–100 iu/kg for interventional procedures according to operator 
preference). In both groups following completion of the cardiac procedure the vascular 
sheath was removed in the catheterisation laboratory and compression applied with the 
helix device until no visible bleeding was apparent. 
 
Following sheath removal patients were immediately ambulated and transferred to the 
recovery area. An oximeter was placed on the patients index finger, transient ulnar 
compression was applied to the patients ulnar artery, and patent haemostsis was achieved 
by reducing helix compression until an oximeter signal reappeared (Figure 2). In the HC 
group, compression time protocol was 60 minutes per 2500 iu of heparin administered. In 
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the AC group, we used our in-house AHP (Table 1) with the aim of achieving haemostasis 
within 60 minutes, irrespective of heparin dose. 
Before applying the StatSeal® Advanced disc, the radial sheath is withdrawn 1-2 centimetres 
allowing space for the disc to be placed directly over the puncture site. This is then covered 
with a transparent adherent dressing before the HelixTM compression device is applied on 
top of disc. The sheath is then withdrawn while tightening the helix band (Figure 3).  In both 
groups, after the allocated compression time had elapsed, pressure in the HelixTM was 
completely released. Following this, the HelixTM is then removed and the access site is 
assessed for any re-bleeding or haematoma. In the event of any re-bleeding the HelixTM was 
reapplied for a further 20 minutes before attempting the removal protocol again. In the AC 
group, the transparent dressing (with StatSeal® Advanced Disc underneath) was left in-situ 
and patients were advised to remove this after 24 hours. 
STUDY ENDPOINTS 
The primary (efficacy) endpoint was time to haemostasis defined as the total time elapsed 
from removal of the sheath to removal of the compression device with achievement of 
satisfactory haemostasis. Secondary (safety) endpoints were the incidence of (i) re-bleeding 
defined as any visible bleeding from the access site after initial removal of the compression 
device that necessitated re-application of the compression device, (ii) haematomas 
classified according to the Early Discharge After Transradial Stenting of Coronary Arteries 
(EASY) haematoma grading19  and (iii) radial artery patency checked within 24 hours 
following removal of the compression device using a reverse Barbeau’s Test.20 
STATISTICAL ANALYSIS 
Normality was assessed using the Shapiro-Wilk test, histograms and Q-Q plots. Normally 
distributed data are shown as mean ± SD and non-parametric data as median (25-75% 
quartiles). Differences between the study groups were assessed using independent t-test 
(for continuous data) or chi-squared test (for categorical data). Statistical analysis was 
performed using Statistical Package for Social Sciences, SPSS v22.0 (Chicago, IL, USA). A p-
value of <0.05 was considered statistically significant. 
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RESULTS 
POPULATION CHARACTERISTICS 
We enrolled 389 patients (191 randomised to HC and 198 patients to AC) between May and 
November 2017. Patient characteristics are listed in Table 2. Our study population had a 
mean age of 66, with a male: female ratio of approximately 3:1. Baseline characteristics 
were similar in both groups apart from a higher proportion of coronary intervention in HC 
group (55% vs 42.4%, P=0.013). Importantly, there was no significant difference in dose of 
heparin in the groups. Over 92% of participants in both groups had their procedure 
performed using a 6 Fr sheath. 
TIME TO HAEMOSTASIS (PRIMARY OUTCOME) 
The primary end point of time to haemostasis was significantly lower in the AC group at 79.7 
± 41.2 minutes as compared to standard compression in the HC group 165.8 ± 63.1 minutes,  
p<0.001 ( figure 4 ) 
SECONDARY SAFETY OUTCOMES 
There was no significant difference in re-bleeding between the HC and AC groups (3.7% vs 
5.6%, p=0.37) but the incidence of EASY grade I/II haematoma was more frequent in the AC 
group (4.7% vs. 12.1%, p=0.009). No patients had a haematoma larger than grade II. The 
rate of RAO was lower in the AC group but this difference did not reach statistical 
significance (6.3% vs 4.1%, p=0.33) 
DISCUSSION 
In this randomized control trial, we evaluated the efficacy of an accelerated haemostatic 
protocol (AHP) in conjunction with the StatSeal Advanced® haemostatic disc. Using an AHP, 
reduced the haemostasis time to half that of our conventional haemostasis protocol.  
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Moreover, this reduction was achieved without a significant increase in vascular 
complications such as re-bleeding and RAO.  This is in-keeping with previous studies of 
haemostatic adjuncts following percutaneous vascular interventions.21-23 Use of StatSeal® 
for TRA has been evaluated in small observational and randomised trials using various radial 
artery compression devices including the TR BandTM (Terumo, Japan) and Safeguard® (Merit 
Medical, USA). Condry et al21, using TR band,  achieved a time to haemostasis 205+/-52  in 
the control group versus 77+/-20 minutes with Statseal and noted no significant increase in 
bleeding or reduction in post-procedural radial artery patency.15 Another observational 
study by De Korompay et al22 found low complication rates of haematoma (0.92%) and 
radial artery occlusion (0.3%), while compression time was reduced to nearly 1 hour. 
In our study, the AC group had a higher incidence of haematoma but an equivalent rate of 
re-bleeding. This may be related to the reduced compression time not allowing for adequate 
haemostasis as has been observed in other studies with very low compression times20, 22. 
Additionally the use of a 14mm round disc shaped Statseal may have reduced bleeding at 
the skin puncture but led to less effective haemostasis at the arterial puncture site. The 
small diameter of the disc may have led to uneven compression over the puncture site with 
most of the pressure over the skin puncture and less over the deeper, more proximal 
arterial puncture. The development of a rectangular shaped Statseal that allows for more 
even compression over a wider area may be further evaluated in the future, but was not 
available at the time of our study. All the haematomas observed in our participants were 
small (EASY grade II or less) and did not require any intervention. The rate of re-bleeding 
was the same in both groups and was successfully managed in all patients by reapplying 
compression.  
The rate of RAO was the 35% higher in the HC group. Although this did not achieve 
statistical significance this may be due to a lack of power in our study. This observation 
requires further study as a reduction in RAO is an important objective.  RAO has been 
observed in 1-30% of procedures and reduces options for repeat procedures, haemodialysis 
fistulae and coronary bypass grafting. Interventional operators employ a number of 
measures to prevent RAO, including minimising sheath size, utilising patent haemostasis, 
minimising access-site compression time and using adequate anticoagulation and 
vasodilator therapies.9, 24, 25 At our high volume, transradial centre, we routinely employ all 
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these strategies and this may account for the low overall incidence of RAO seen in our 
study, despite assessing RAO at a time-point when this is often more frequent.26-28 
Additionally, the numerically lower rate of RAO observed in the AC group is reassuring as 
haematoma is often associated with higher rates of RAO due to more prolonged and 
occlusive pressure, often applied in response to the development of a haematoma. 
In our study, we noted a significant reduction in compression time with the AHP and 
Statseal advance. This is not only important in terms of patient comfort and convenience, 
but also promotes early ambulation and increases patient satisfaction.20, 22. Additionally, the 
decreased requirement for nursing input may contribute to the reduced costs when TRA is 
compared to TFA for coronary procedures29. Importantly same day discharge is more likely 
when TRA is used, leading to markedly reduced costs compared to TFA, not only because of 
fewer complications but because of less utilisation of hospital resources.29-34 Patients are 
often still advised to be monitored for at least 4 hours post coronary intervention,19, 35-38 
however, optimisation of post procedure care with the use of dedicated radial lounges has 
improved efficiency and patient satisfaction.39 The use of AHPs may add further benefit in 
facilitating early ambulation and discharge. 
Other recent studies have investigated patent haemostasis and AHPs with various types of 
adjunctive haemostasis devices including a chitosan-based pad40 and QuikClot.41 They have 
also demonstrated decreased haemostasis times, however in these studies allergic reactions 
to the materials in the devices were observed. Interestingly, no such adverse immunological 
reactions were observed with the StatSeal Advanced® disc in our study.  The StatSeal 
Advanced® haemostatic disc therefore appears to be a safe adjunct to achieving patent 
haemostasis with an AHP by allowing substantial reduction in compression time, which may 
lead to reduced nursing time and hospital costs. 
 
LIMITATIONS 
This trial was conducted at a single centre with considerable radial expertise and hence our 
findings may not be generalizable to other centres with less TRA expertise, or in centres 
where an alternative compression device is used. Our study is also limited by a small sample 
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size which limits the ability to interpret the results for study end points with low incidence 
such as radial artery occlusion and therefore a larger multi-centre randomised trial is 
required to corroborate our findings.  Evaluation of radial artery patency in our study did 
not include ultrasound assessment, which may be more robust. Furthermore, radial artery 
patency is highly associated with the duration of haemostatic compression and although we 
report that the StatSeal Advanced® disc facilitates safe reduction of the haemostatic time, 
we did not include a third study arm comprising of the AHP alone.  Finally, patients were not 
followed up to assess radial artery patency after a longer time period but it would be 
expected that the rate of RAO would decrease with time, as has been demonstrated in 
multiple studies.10, 16, 18, 26, 27 
CONCLUSIONS 
Use of an AHP is feasible and reduces compression time.  More rapid haemostasis can be 
achieved with use of an AHP and the StatSeal® disc without conferring significant additional 
complications following TRA. The Statseal Advanced® disc is a safe and effective adjunct to 
compression devices and may allow earlier mobilisation and reduce nursing input following 
TRA procedures.  The effects on radial artery patency warrant further investigation in larger 
trials. 
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Table 1: Accelerated Haemostasis Protocol used with the StatSeal® Advanced Disc. 
This applies to all patients regardless of antithrombotic therapy. 
 
1. Prepare site by cleaning and drying the patient’s wrist area.  
2. Withdraw transradial sheath 3-4 cm. 
3. Centre StatSeal® Advanced Disc over the dermatotomy and secure it with a 
transparent dressing.  Apply product label next to StatSeal® Advanced Disc. 
4. Apply the HelixTM band around the wrist, centring the HelixTM pressure pad directly 
over the arteriotomy, and tighten the band while slowly removing the sheath. 
5. Observe the site for bleeding or swelling. 
6. Transfer patient to recovery area. 
7. Apply a pulse oximeter to the patient’s thumb or index finger. 
8. Perform a Barbeau test by compressing the ulnar artery.  
9. Gradually loosen the HelixTM band until a Barbeau A, B or C waveform appears - 
document the waveform. 
10. Occluded ulnar artery + A, B or C waveform = PATENT HAEMOSTASIS 
11. Leave HelixTM band in place for 40 minutes. Monitor for bleeding or swelling. 
12. After 40 minutes, immobilize the wrist and slowly reduce all pressure in the HelixTM 
band.  Assess for re-bleeding. 
13. In case of haematoma or re-bleeding then recompress with the HelixTM device for a 
further 20 minutes and observe. 
14. After 20 minutes, if no further bleeding remove the HelixTM band. 
15. Prepare patient for discharge. Instruct patient to avoid lifting or strenuous activity 
with the operative side for 24-48 hours. 
16. Instruct patient to leave the StatSeal® disc dressing in place for 24 hours. 
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Table 2: Baseline Characteristics 
Variable 
 
HC 
n=191 
AC 
n=198 
P value 
 
Age, years 65.7 ± 10.7 66.2 ± 10.8 0.62 
Male 140 (73.3) 133 (67.2) 0.19 
Diabetes 40 (20.9) 48 (24.2) 0.44 
Height (cm) 171.0 ± 9.7 169.7 ± 9.2 0.20 
Weight (Kg) 85.5 ± 17.1 82.8 ± 16.6 0.11 
BMI (Kg/m2) 29.2 ± 5.2 28.8 ± 5.5 0.45 
eGFR, ml/min/1.73 m2 75.7 ± 16.8 77.2 ± 15.6 0.39 
Indication for Procedure 
Elective 
ACS 
 
137 (71.7) 
54 (28.3) 
 
143 (72.2) 
55 (27.8) 
0.91 
 
    
Type of Procedure 
Diagnostic 
    Intervention 
 
86 (45.0) 
105 (55.0) 
 
114 (57.6) 
84 (42.4) 
0.013 
Aspirin use 160 (83.8) 166 (83.8) 0.99 
P2Y12 inhibitor use 146 (76.4) 146 (73.7) 0.54 
Anticoagulation 
(NOAC/Warfarin) 
25 (13.1) 23 (11.6) 0.66 
Heparin dose 5,754 ± 2,161 5,990 ± 2,203 0.29 
Sheath size  
4 Fr 
5 Fr 
6 Fr 
7 Fr 
8 Fr 
 
0 (0) 
11 (5.8) 
176 (92.6) 
2 (1.1) 
1 (0.5) 
 
1 (0.5) 
5 (2.5) 
188 (95.4) 
3 (1.5) 
0 (0) 
0.32 
Pulse oximetry used (BT) 186 (97.4) 190 (96.5) 1.60 
Values are mean ± SD or n (%).   
P-value from independent t-test for continuous variables and Pearson's chi-squared 
test (or Fisher’s exact test where appropriate) for categorical variables. 
ACS, acute coronary syndrome; BT, Barbeau Test; NOACs, Novel Oral Anticoagulants 
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Table 3: Primary and secondary outcomes. 
Variable 
 
No Statseal (HC) 
n=191 
With Statseal (AC)  
n=198 
P value 
 
Radial artery occlusion 
(RAO) 
14 (6.3) 13 (4.1) 0.33 
Re-bleeding 7 (3.7) 11 (5.6) 0.37 
Haematoma 9 (4.7) 24 (12.1) 0.009 
Compression time, mins 165.8 ± 63.1 79.7 ± 41.2 <0.001 
Values are mean ± SD or n (%).   
P-value from independent t-test for continuous variables and Pearson's chi-squared 
test (or Fisher’s exact test where appropriate) for categorical variables. 
ACS, acute coronary syndrome; BT, Barbeau Test 
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Figure 1: Study devices: (A) HelixTM compression device and (B) StatSealTM Advance disc 
 
 
 
Figure 2: How to achieve patent haemostasis 
 
A B 
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Figure 3: Positioning of StatSealTM Advanced Disc  
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Figure 4: Time to haemostasis. 
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Highlights 
 Radial artery occlusion has been linked to flow reduction and prolonged compression.  
We aimed to investigate the effectiveness and safety of an accelerated band removal 
protocol, facilitated by a hemostasis promoting pad with patent haemostasis. 
 Our randomized trial of 389 patients (191 patients received standard haemostatic com-
pression and 198 received accelerated compression). The compression time was signifi-
cantly reduced by more than 1/3 of the time, compared to standard compression (165.8 
± 63.1 versus 79.7 ± 41.2 minutes, p<0.001).  
 There were no significant differences in re-bleeding and RAO between groups (3.7% ver-
sus 5.6%, p=0.37 and 6.3% versus 4.1%, p=0.33) respectively. Incidence of haematoma 
was higher in accelerated compression group (4.7% versus 12.1%, p=0.009). 
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